Xiaosong Shi

Dr. Xiaosong Shi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Chest
Verified
Journal Article
Closed access
MSMaanasi Samant
Maanasi Samant
JKJames G. Krings
James G. Krings
DLDaphne Lew
Daphne Lew
CGCharles W. Goss
Charles W. Goss
TKTammy Koch
Tammy Koch
MCMario Castro
Mario Castro

14 July 2024 in Contemporary Clinical Trials
Verified
Journal Article
Open access
XSXiaosong Shi
Xiaosong Shi
JWJo A. Wick
Jo A. Wick
DCDanielle N. Christifano
Danielle N. Christifano
SCSusan E. Carlson
Susan E. Carlson
ABAlexandra R. Brown
Alexandra R. Brown
BGByron J. Gajewski
Byron J. Gajewski
Background: Early preterm birth (ePTB) - born before 34 weeks of gestation - poses a significant public health challenge. Two randomized trials indicated an ePTB reduction among pregnant women receiving high-dose docosahexaenoic acid (DHA) supplementation. One of them is Assessment of DHA on Reducing Early Preterm Birth (ADORE). A survey employed in its secondary analysis identified women with low DHA levels, revealing that they derived greater benefits from high-dose DHA supplementation. This survey's inclusion in future trials can provide critical insights for informing clinical practices. Objective: To optimize a Phase III trial design, ADORE Precision, aiming at assessing DHA supplement (200 vs. 1000 mg/day) on reducing ePTB among pregnant women with a low baseline DHA. Methods: We propose a Bayesian Hybrid Response Adaptive Randomization (RAR) Design utilizing a finite mixture model to characterize gestational age at birth. Subsequently, a dichotomized ePTB outcome is used to inform trial design using RAR. Simulation studies were conducted to compare a Fixed Design, an Adaptive Design with early stopping, an ADORE-like Adaptive RAR Design, and two new Hybrid Designs with different hyperpriors. Discussion: Simulation reveals several advantages of the RAR designs, such as higher allocation to the more promising dose and a trial duration reduction. The proposed Hybrid RAR Designs addresses the statistical power drop observed in Adaptive RAR. The new design model shows robustness to hyperprior choices. We recommend Hybrid RAR Design 1 for ADORE Precision, anticipating that it will yield precise determinations, which is crucial for advancing our understanding in this field.

19 February 2024 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
XSXiaosong Shi
Xiaosong Shi
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
JWJo A. Wick
Jo A. Wick
DSDavid Streeter
David Streeter
JTJeffrey A. Thompson
Jeffrey A. Thompson
BGByron Gajewski
Byron Gajewski
Slow patient accrual in cancer clinical trials is always a concern. In 2021, the University of Kansas Comprehensive Cancer Center (KUCC), an NCI-designated comprehensive cancer center, implemented the Curated Cancer Clinical Outcomes Database (C3OD) to perform trial feasibility analyses using real-time electronic medical record data. In this study, we proposed a Bayesian hierarchical model to evaluate annual cancer clinical trial accrual performance. The Bayesian hierarchical model uses Poisson models to describe the accrual performance of individual cancer clinical trials and a hierarchical component to describe the variation in performance across studies. Additionally, this model evaluates the impacts of the C3OD and the COVID-19 pandemic using posterior probabilities across evaluation years. The performance metric is the ratio of the observed accrual rate to the target accrual rate. Posterior medians of the annual accrual performance at the KUCC from 2018 to 2023 are 0.233, 0.246, 0.197, 0.150, 0.254, and 0.340. The COVID-19 pandemic partly explains the drop in performance in 2020 and 2021. The posterior probability that annual accrual performance is better with C3OD in 2023 than pre-pandemic (2019) is 0.935. This study comprehensively evaluates the annual performance of clinical trial accrual at the KUCC, revealing a negative impact of COVID-19 and an ongoing positive impact of C3OD implementation. Two sensitivity analyses further validate the robustness of our model. Evaluating annual accrual performance across clinical trials is essential for a cancer center. The performance evaluation tools described in this paper are highly recommended for monitoring clinical trial accrual.

1 September 2021 in Children and Youth Services Review
Verified
Journal Article
Closed access
AWAnne Williford
Anne Williford
Julia SharpJulia Sharp
Julia Sharp
AFAlex Fout
Alex Fout
CSCasey Schafer
Casey Schafer
XSXiaosong Shi
Xiaosong Shi
DIDebbie Isen
Debbie Isen

17 June 2024 in Statistics in Medicine
Verified
Journal Article
Closed access
XSXiaosong Shi
Xiaosong Shi
JWJo A. Wick
Jo A. Wick
RMRenee' L. Martin
Renee' L. Martin
JBJonathan Beall
Jonathan Beall
RSRobert Silbergleit
Robert Silbergleit
BGByron Gajewski
Byron Gajewski